Peer review reports
From: Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy
| Original Submission |
| 3 Dec 2023 |
Submitted |
Original manuscript
|
| Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
| 7 Jan 2024 |
Reviewed |
Reviewer Report
|
| 29 Jan 2024 |
Reviewed |
Reviewer Report
|
| 6 Feb 2024 |
Author responded |
Author comments - Liru Li
|
| Resubmission - Version 3 |
| 6 Feb 2024 |
Submitted |
Manuscript version 3
|
| 8 Feb 2024 |
Author responded |
Author comments - Liru Li
|
| Resubmission - Version 4 |
| 8 Feb 2024 |
Submitted |
Manuscript version 4
|
| 9 Jul 2024 |
Reviewed |
Reviewer Report
|
| Resubmission - Version 5 |
|
Submitted |
Manuscript version 5
|
| Publishing |
| 9 Jul 2024 |
Editorially accepted |
|
| 17 Jul 2024 |
Article published |
10.1186/s12885-024-12621-y
|
Learn about peer review
